AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01616381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for sildenafil 40mg x 3 daily
Trial: NCT03975387
Drug: ASTX295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
Trial: NCT00833794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03072992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.v. solution, once weekly for 12 weeks
Trial: NCT03214510
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via thoracic epidural catheter
Trial: NCT02080247
Drug: Skin care regimen with Calmoseptine ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
Trial: NCT02080247
Drug: Skin care regimen with Destin ointment
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
Trial: NCT00434421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
Trial: NCT02925702
Drug: Radium 223 55mBq/Kg every 4 weeks intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 55kBq/kg infusion IV every 4 weeks
Trial: NCT02489526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will receive the corresponding amount of placebo.
Trial: NCT00768326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks
Trial: NCT00269776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
Trial: NCT01925937
Drug: placebo for coenzyme Q10
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02246621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02111044
Drug: ITF2984 500 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF2984 500 mcg sc b.i.d for 4 weeks
Trial: NCT02111044
Drug: ITF2984 1000 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF2984 1000 mcg sc b.i.d for 4 weeks
Trial: NCT02111044
Drug: ITF2984 2000 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF2984 2000 mcg sc b.i.d for 4 weeks
Trial: NCT01069939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, capsule, 72 weeks
Trial: NCT00750815
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
Trial: NCT00853320
Drug: Roxicodone™ tablet 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxicodone™ tablet 15 mg, single dose fasting
Trial: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of E2 + DRSP as a tablet
Trial: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of E2 + DRSP as a tablet
Trial: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 3 (80458755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of E2 + DRSP as a tablet
Trial: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 4 (80458720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of E2 + DRSP as a tablet
Trial: NCT00653614
Drug: E2/DRSP (BAY 86-4891) dose 5 (80458712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of E2 + DRSP as a tablet
Trial: NCT00653614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration in each arm
Trial: NCT01012934
Drug: Fosamax Tablets, 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 70 mg, single-dose fasting
Trial: NCT02657915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02657915
Drug: BIIB033 100mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02332148
Drug: Placebo for 3VM1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream placebo for 3VM1001; cream without 3VM1001
Trial: NCT00406068
Drug: Mycobacterial cell wall-DNA complex
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
Trial: NCT01591785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
Trial: NCT00849901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
Trial: NCT00849901
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-40 milligram (mg), PO, QD, for up to 38 weeks
Trial: NCT01541891
Drug: Active Comparator: SYSTANE ® Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
Trial: NCT01748630
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00661596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02664103
Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT01056965
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
Trial: NCT00625443
Drug: Blinded (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months
Trial: NCT04274114
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder
Trial: NCT00194753
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mg/m2 IV weekly x 12
Trial: NCT00194753
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/m2 PO daily for 12 weeks
Trial: NCT03861936
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
Trial: NCT04530903
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nacl 0.9% (0.5ml) per injection site
Trial: NCT01725698
Drug: Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01437501
Drug: placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of dilute pineapple and lime juice daily for 84 days.
Trial: NCT01707420
Drug: liquid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
Trial: NCT03124420
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
Trial: NCT01974648
Drug: propofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01156870
Drug: SAR566658
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Trial: NCT02036242
Drug: Sufentanil (Opioid plus local anesthetic)
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
Trial: NCT03589495
Drug: N Acetyl L Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg n acetyl cysteine dissolved in dextrose5%
Trial: NCT01966328
Drug: 36% Resolvine Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36% Resolvine Intravitreal Injection
Trial: NCT01966328
Drug: 9% Resolvine Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9% Resolvine Intravitreal Injection
Trial: NCT01033552
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
Trial: NCT01471015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
Trial: NCT02576444
Drug: AZD2281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
Trial: NCT02576444
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
Trial: NCT02576444
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dose will be available no earlier than March 2016.
Trial: NCT02576444
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
Trial: NCT01256684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppository
Trial: NCT00669942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to AIN457
Trial: NCT03586700
Drug: Placebo Xiao zhong fang granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
Trial: NCT00946166
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg daily in the evening for a maximum of 14 days
Trial: NCT00946166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
Trial: NCT02996682
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT02246920
Drug: Flonase®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg/actuation Nasal Spray
Trial: NCT02246920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive Nasal Spray
Trial: NCT02167620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
Trial: NCT00086996
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
Trial: NCT02266264
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
Trial: NCT00034684
Drug: Farnesyl Protein Transferase Inhibitor
RxNorm normalized name: farnesyl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00612170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral tablet once a day dosing
Trial: NCT00864981
Drug: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03366675
Drug: AZD2811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2811 100mg/vial
Trial: NCT01789905
Drug: Tigecycline (Tygacil)
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Trial: NCT01726205
Drug: Placebo drug, normal saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00492960
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsules
Trial: NCT00003674
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01364194
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
Trial: NCT00378131
Drug: RC-1291
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00378131
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01054586
Drug: Intervention A Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of \<2.0.
Trial: NCT01054586
Drug: Intervention B Reduced Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
Trial: NCT01054586
Drug: Intervention C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
Trial: NCT01960569
Drug: active product ( Thrombexx) assigned to arm 1
RxNorm normalized name: collagen,activated Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
Trial: NCT03702894
Drug: Clavamox
RxNorm normalized name: Clavamox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
Trial: NCT03702894
Drug: Augmentin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
Trial: NCT02608788
Drug: S.L.®
RxNorm normalized name: Sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Trial: NCT02608788
Drug: Difflam Forte ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Trial: NCT02608788
Drug: Acular®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Trial: NCT02608788
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Trial: NCT02336854
Drug: Tacrobell tab. 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02336854
Drug: Prograf cap. 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00702195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo (administered under protocol 38805)
Trial: NCT00702195
Drug: recFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU recFSH daily (reference group administered under protocol 38807)
Trial: NCT00724477
Drug: INEGY
RxNorm normalized name: Ezetimibe/Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
Trial: NCT02409290
Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Locally-used WHO-approved MDR-TB regimen
Trial: NCT02409290
Drug: Kanamycin
RxNorm normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
Trial: NCT03625687
Drug: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
Trial: NCT04553705
Drug: Omega 3/Nigella Sativa Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone
Trial: NCT04553705
Drug: Omega 3/Nigella Sativa Oil/Indian Costus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements
Trial: NCT04553705
Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)
Trial: NCT01396226
Drug: AZD2927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of AZD2927 administered as an iv infusion
Trial: NCT01396226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo administered as an iv infusion
Trial: NCT01936636
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01269762
Drug: LipoCol Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
Trial: NCT04038710
Drug: Triple combination therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
Trial: NCT02419456
Drug: MK-2048A IVR (Low Dose)
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
Trial: NCT02419456
Drug: MK-2048A IVR (Original Dose)
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
Trial: NCT01698476
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no